Haemophilus influenzae Type b conjugate Vaccine (Beijing Zhifei Luzhu Biopharmaceutical)

B型流感嗜血杆菌结合疫苗（智飞生物）

Report date: 2026/05/28 20:00:21

Base Information

Drug NameHaemophilus influenzae Type b conjugate Vaccine (Beijing Zhifei Luzhu Biopharmaceutical)
Drug Alias Name喜菲贝
ClassificationVaccines > National Immunization Program > Non-immunization program vaccine(Class II)Vaccines > Application > Prophylactic vaccineVaccines > Biological material > Bacterial vaccine +[4] 
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsMeningitisArthritisCellulitis +[8] 
Global Approved IndicationsHaemophilus Infections
Approved Indications in ChinaHaemophilus Infections
Original Approved Country/TerritoryMainland China
Original Approved Date2011/12/31
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBeijing Zhifei Lvzhu Biopharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Zhifei Lvzhu Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsMeningitisArthritisCellulitis +[7] 
Inactive IndicationsInfections

Other Information

ATC CodeJ07AG01
Related LinksWikipediaDrugBankKEGG